Search results
Results From The WOW.Com Content Network
U.S. officials on Monday approved the first long-acting drug to protect babies and toddlers against a respiratory virus that sends tens of thousands of American children to the hospital each year.
It requires the FDA to submit an annual report to congressional committees that includes: (1) the number of devices approved in the preceding year for which there is a pediatric subpopulation that suffers from the disease; (2) the number of approved devices labeled for use in pediatric patients; (3) the number of fee-exempt devices approved ...
Pulmonary surfactant is used as a medication to treat and prevent respiratory distress syndrome in newborn babies. [1] Prevention is generally done in babies born at a gestational age of less than 32 weeks. [1] It is given by the endotracheal tube. [1] Onset of effects is rapid. [2] A number of doses may be needed. [2]
The smallest device approved by the FDA, the HeartMate II, weighs about 1 pound (0.45 kg) and measures 3 inches (7.6 cm). This has proven particularly important for women and children, for whom alternatives would have been too large. [45] As of 2017, HeartMate III has been approved by the FDA.
The Broselow Tape, also called the Broselow pediatric emergency tape, is a color-coded length-based tape measure that is used throughout the world for pediatric emergencies. The Broselow Tape relates a child's height as measured by the tape to their weight to provide medical instructions including medication dosages , the size of the equipment ...
The Coventor device was developed in a very short time and approved on April 15, 2020, by the FDA, only 30 days after conception. The mechanical ventilator is designed for use by trained medical professionals in intensive care units and easy to operate. It has a compact design and is relatively inexpensive to manufacture and distribute.
In April 2023, the FDA approved the use of Prevnar 20 vaccine to prevent pneumococcal disease in children aged six weeks to 17 years. [30] [31] [32] Pneumovax 23 (pneumococcal vaccine polyvalent) was approved for medical use in the United States in 1983. [33] [34]
However, according to the Centers for Disease Control and Prevention, an estimated 58,000 to 80,000 children under the age of 5 are hospitalized each year due to complications caused by an RSV ...